Claims
- 1. A wound-healing composition, comprising:
a wound-treating component; and vesicles, wherein the vesicles comprise:
a phospholipid which is a stable vesicle former; and ATP.
- 2. The wound-healing composition of claim 1, wherein the wound-treating component comprises at least one member selected from the group consisting of an antiseptic, an antibiotic, and an anesthetic.
- 3. The wound-healing composition of claim 1, wherein the wound-treating component comprises becaplermin.
- 4. The wound-healing composition of claim 1, wherein the vesicles have a fusion rate of at least 20 vesicle fusions/second.
- 5. The wound-healing composition of claim 1, wherein the vesicles further comprise another polar lipid.
- 6. The wound-healing composition of claim 1, wherein the vesicles further comprise at least one member selected from the group consisting of PEG, a raft former, and a fusion protein.
- 7. The wound-healing composition of claim 1, wherein the vesicles further comprise PEG.
- 8. The wound-healing composition of claim 5, wherein the phospholipid or the another polar lipid that has the structure of formula (I)
- 9. The wound-healing composition of claim 8, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 6L has a structure selected from the group consisting of formulas (VIII), (IX) or (X) 7and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 8
- 10. The wound-healing composition of claim 9, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or mixtures thereof.
- 11. The wound-healing composition of claim 9, wherein the wound-treating component comprises at least one member selected from the group consisting of an antiseptic, an antibiotic, and an anesthetic.
- 12. The wound-healing composition of claim 9, wherein the wound-treating component comprises becaplermin.
- 13. The wound-healing composition of claim 1, wherein the phospholipid has the structure of formula (I′)
- 14. The wound-healing composition of claim 1, wherein the vesicles further comprise at least one member selected from the group consisting of a polar lipid which is not a stable vesicle former and PEG,
wherein the phospholipid has a structure of formula (I) X-L-Z2 (I) wherein X is H, or has a structure of formula (II) 12B is a cation or an alkyl group, A is a H or an alkyl group, L is an alkyl further missing two hydrogen atoms, and each Z is independently H, E, or the structure of formula (XI), 13wherein E is an alkyl or alkenyl, and when one Z is H, the other Z is not H.
- 15. The wound-healing composition of claim 14, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 14L has a structure selected from the group consisting of formulas (VIII), (IX) or (X) 15and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 16
- 16. The wound-healing composition of claim 14, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or mixtures thereof.
- 17. The wound-healing composition of claim 14, further comprising at least one member selected from the group consisting of PEG, a raft former, and a fusion protein.
- 18. The wound-healing composition of claim 14, wherein the vesicles further comprise a polar lipid which is not a stable vesicle former, wherein the polar lipid which is not a stable vesicle former has the structure selected from the group consisting of formulas (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXV) and (XXVI)
- 19. The wound-healing composition of claim 14, wherein the wound-treating component comprises at least one member selected from the group consisting of an antiseptic, an antibiotic, and an anesthetic.
- 20. The wound-healing composition of claim 14, wherein the wound-treating component comprises becaplermin.
- 21. A wound-healing composition, comprising:
at least one member selected from the group consisting of becaplermin, an antiseptic, an antibiotic, and an anesthetic; and vesicles, wherein the vesicles comprise:
a phospholipid which is a stable vesicle former; a polar lipid which is not a stable vesicle former; and ATP.
- 22. The wound-healing composition of claim 21,
wherein the phospholipid which is a stable vesicle former is at least one member selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine; and wherein the polar lipid which is not a stable vesicle former has the structure selected from the group consisting of formulas (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXV) and (XXVI) 1920
- 23. The wound-healing composition of claim 21, wherein the vesicles further comprise PEG.
- 24. A method for promoting wound healing, comprising contacting a wound with the wound-healing composition of claim 1.
- 25. The method of claim 24, wherein the wound is a superficial wound.
- 26. A method for promoting wound healing, comprising contacting a wound with the wound-healing composition of claim 21.
- 27. The method of claim 26, wherein the wound is a superficial wound.
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 10/397,048, A DIRECT CELLULAR ENERGY DELIVERY SYSTEM, to William D. Ehringer and Sufan Chien, filed Mar. 25, 2003, which claims priority to U.S. provisional application Serial No. 60/380,762, FUSOGENIC LIPID VESICLES, to William D. Ehringer and Sufan Chien, filed May 14, 2002, both of which are incorporated herein by reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60380762 |
May 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10397048 |
Mar 2003 |
US |
Child |
10627195 |
Jul 2003 |
US |